TEVA · Teva- Pharmaceutical Industries Ltd
United States · RS rating 91 · As of 2026-11-03
| Price | 41.91 USD |
|---|---|
| 1-day change | +3.0% |
| RS rating (overall / 1M / 3M / 12M) | 91 / 73 / 90 / 94 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 53 / 79 / 57 |
| Industry group (rank) | Medical-Generic Drugs (136) |
| EPS growth Q/Q | +10.8% |
| Sales growth Q/Q | +5.2% |
| Distance from 52-week high | +0.4% |
| Market cap (USD) | $36.3B |